Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Accumulated Expenses (2021 - 2025)

Stoke Therapeutics has reported Other Accumulated Expenses over the past 5 years, most recently at $1.1 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 40.77% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 40.77%, while the annual FY2025 figure was $1.1 million, 40.77% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $1.1 million at Stoke Therapeutics, up from $795000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $2.1 million in Q1 2025 and troughed at $426000.0 in Q3 2022.
  • A 5-year average of $843058.8 and a median of $750000.0 in 2022 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: decreased 12.14% in 2024 and later soared 111.63% in 2025.
  • Year by year, Other Accumulated Expenses stood at $540000.0 in 2021, then fell by 5.74% to $509000.0 in 2022, then surged by 68.37% to $857000.0 in 2023, then fell by 12.14% to $753000.0 in 2024, then skyrocketed by 40.77% to $1.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for STOK at $1.1 million in Q4 2025, $795000.0 in Q3 2025, and $1.8 million in Q2 2025.